TMCnet News
INC Research Strengthens Real World & Late Phase and Global Consulting Capabilities with Key Leadership AppointmentsAdditional senior-level expertise enhances global CRO’s strategic services offering, helping large pharma to meet their commercial objectives while strongly positioning the Company to capitalize on this growing market opportunity RALEIGH, N.C., March 30, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced it has appointed several new senior leaders to strengthen its Real World & Late Phase (RWLP) and Global Consulting offerings to biopharmaceutical customers worldwide. INC’s RWLP team is dedicated to real world, evidence-based data collection and works in close collaboration with the Company’s Global Consulting business to support customers at every stage of their product and portfolio development. INC’s expanded team will help maximize value for sponsors throughout the product lifecycle, from concept to commercialization, by providing consultative and operational expertise in the delivery of real-world evidence. The appointments reinforce INC's continued focus on providing customers with strategic consulting services along with the right evidence to make the best clinical decisions in this rapidly expanding segment of the clinical research environment. “Healthcare stakeholders are increasingly seeking real-world evidence to support regulatory, reimbursement and prescribing decisions,” said Christian Tucat, MBA, Executive Vice President, RWLP and Global Consulting. “It’s never too early to have a commercial plan in drug development, and that’s why we’ve continued to grow our team. The leadership we’ve added in RWLP and Global Consulting have extensive industry connections and understand the complexities of Late Phase studies, moving new therapies from a controlled and experimental environment of a clinical trial to a real-world situation, and then to market. By beginning with the end in mind, we ensure we gain the right outcome for our sponsors as well as for patients, physicians, payers and regulators.” The newly appointed experts to INC’s RWLP and Global Consulting teams include:
INC’s Global Consulting team provides global advisory and implementation support service for the biopharmaceutical industry. Led by a senior team, the unit is committed to working with customers to deliver innovative and practical solutions that support their business needs from concept through development to commercialization. Since 2011, the dedicated Real World and Late Phase group has conducted 200+ Real World and Late Phase studies globally and has more than 400 staff currently working in this area. INC has a wealth of experience in helping customers achieve their commercial goals. The recent appointments further strengthen INC’s capabilities to capitalize on the growing Phase IV and Post Approval CRO market opportunity. For more information on INC’s RWLP and consulting services, visit the website or watch this video from Executive Vice President, RWLP and Global Consulting, Christian Tucat. About INC Research CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: [email protected] Press/Media Contacts: Lori Dorer Senior Director, Corporate Communications Phone: +1 (919) 745-2890 Email: [email protected] |